Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)

Inventors

MCGRATH, Lara Lewis • DÉPIS, Fabien • HU, Changyun • Presta, Leonard G. • BUGGÉ, Joshua Adam

Assignees

Gilead Sciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12297282-B2

Patent

Publication Date

2025-05-13

Expiration Date


Abstract

Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.

Core Innovation

The disclosed subject matter relates to an isolated nucleic acid encoding a heavy chain and/or a light chain of an antibody that binds human CCR8. The antibody is defined by complementarity determining regions, including HCDR1 comprising the amino acid sequence of SEQ ID NO: 84 or 100, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, HCDR3 comprising the amino acid sequence of SEQ ID NO: 86, and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO: 87, 88, and 89.

The disclosure further includes antibody formats and associated nucleic acid and host-cell embodiments for producing CCR8-binding antibodies and related fusion protein constructs. It states fusion protein compositions that include CCL1 or active fragments, and MC148 or active fragments, with an Fc region, and describes engineered Fc modifications to enhance cell killing, including afucosylation.

Therapeutic compositions and administration are disclosed for treating CCR8-expressing cancers, including tumors with tumor-infiltrating Tregs and refractory and checkpoint-inhibitor resistant disease. The disclosure describes Treg depletion via ADCC and CDC, and supports subject-selection and functional assessment using assays such as KinExA, on-cell Kd, FACS, flow cytometry, immunohistochemistry, Q-PCR, RT-PCR, Western blot, and ELISA.

Claims Coverage

The consolidated claim coverage provides one independent claim concept, centered on an isolated nucleic acid encoding a CCR8-binding antibody with defined complementarity determining region sequences, for a total of 6 inventive CDR features. Dependent-claim context further narrows the subject matter to antibody formats, fusion proteins, and engineered Fc modifications, including afucosylated antibodies.

Isolated nucleic acid encoding a CCR8-binding antibody with specified HCDRs and LCDRs

An isolated nucleic acid encoding a heavy chain and/or a light chain of an antibody that binds human CCR8, wherein the heavy chain comprises HCDR1 comprising the amino acid sequence of SEQ ID NO: 84 or 100, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 86; and wherein the light chain comprises LCDR1 comprising the amino acid sequence of SEQ ID NO: 87, LCDR2 comprising the amino acid sequence of SEQ ID NO: 88, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 89.

The core claim coverage centers on an isolated nucleic acid defining a human CCR8-binding antibody heavy and light chain by specific HCDR and LCDR amino-acid sequences corresponding to SEQ ID NOs: 84/100, 85, 86, 87, 88, and 89. The available dependent-claim context further refines the subject matter to antibody formats, fusion proteins, and engineered constructs directed to enhanced cell killing.

Stated Advantages

Provides a CCR8-binding antibody defined by specified complementarity determining region sequences.

Supports therapeutic targeting of CCR8-expressing tumor-infiltrating Tregs and/or CCR8-expressing cells, including Treg depletion via ADCC and CDC.

Enables subject-selection based on measuring CCR8 expression.

Enhancement of cell killing via engineered Fc modifications, including afucosylation.

Strong ADCC activity with performance targets described, including EC50 thresholds.

High CCR8 binding affinity with on-cell Kd and KinExA-based measurements.

Improved killing of low-CCR8 targets by requiring afucosylation.

Desired effector function is provided by selecting IgG1 and IgG3 constant regions.

Reduced effector function is provided by selecting IgG4 and IgG2 constant regions.

Documented Applications

Treating cancer by targeting CCR8-expressing tumor-infiltrating Tregs and/or CCR8-expressing cells, including Treg depletion via ADCC and CDC.

Use in combination therapy with immune checkpoint inhibitors and other anticancer/immunomodulatory agents and immunotherapy modalities including cancer vaccines and CAR-T therapy.

Application to solid cancer and blood cancer.

Treating CCR8-expressing cancers, including tumors with tumor-infiltrating Tregs.

Addressing refractory and checkpoint-inhibitor resistant disease, including the possibility of combination therapies.

Targeting CCR8-expressing tumor-infiltrating Tregs for cancer treatment.

Use of antibody/drug fusion and ADC-like conjugates for therapeutic cancer treatment involving the CCR8-binding antibody concept.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.